Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial

Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antivir...

Descripción completa

Detalles Bibliográficos
Autores principales: Holubovska, Olha, Bojkova, Denisa, Elli, Stefano, Bechtel, Marco, Boltz, David, Muzzio, Miguel, Peng, Xinjian, Sala, Frederico, Cosentino, Cesare, Mironenko, Alla, Milde, Jens, Lebed, Yuriy, Stammer, Holger, Goy, Andrew, Guerrini, Marco, Mueller, Lutz, Cinatl, Jindrich, Margitich, Victor, te Velthuis, Aartjan J. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814846/
https://www.ncbi.nlm.nih.gov/pubmed/33469600
http://dx.doi.org/10.1101/2021.01.05.21249237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814846/
https://www.ncbi.nlm.nih.gov/pubmed/33469600
http://dx.doi.org/10.1101/2021.01.05.21249237

Ejemplares similares